NEUROONE MEDICAL TECHNOLOGIES Corp

NEUROONE MEDICAL TECHNOLOGIES Corp is a medical technology company specializing in diagnostic, ablation, and deep brain stimulation technology for brain-related conditions like epilepsy and Parkinson's disease. The company also focuses on ablation and stimulation for pain management throughout the body, and drug delivery systems that include diagnostic and stimulation capabilities. NEUROONE MEDICAL TECHNOLOGIES Corp has received 510(k) clearance from the Food and Drug Administration (FDA) for four devices. These include the Evo cortical electrode technology, used for temporary (less than 30 days) recording, monitoring, and stimulation on the brain's surface, and the Evo sEEG electrode technology, for temporary (less than 30 days) recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. Additionally, the company has clearance for its OneRF Brain Ablation System, which creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures, and the OneRF TN Ablation System, used for creating radiofrequency lesions for pain treatment or functional neurosurgical procedures. The company has a distribution agreement with Zimmer, Inc., granting Zimmer Biomet Holdings, Inc. a license to commercialize and distribute the Evo Cortical, Evo sEEG, and OneRF Brain Ablation System for brain applications. A limited market release of the OneRF TN Ablation System began in December 2025. Other products and indications are currently under development. The company's products include thin film electrode technology, such as cortical sheet and depth electrodes, which are vital for diagnosing neurological disorders like epilepsy, Parkinson's disease, dystonia, and essential tremors. The Evo Cortical portfolio includes various contact configurations of strip and grid electrodes.